Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

African trial of novel HIV vaccine candidate starts

News

The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) – of which the University of Oxford is a lead partner – announced today the start of vaccinations in a Phase I clinical trial of a novel HIV vaccine candidate.

Daily contact COVID-19 testing for students effective at controlling transmission in schools

News

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.

How did people in Europe and SE Asia experience the first COVID-19 wave?

News

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

T-cell ‘training grounds’ behind robust immune system response seen in adenovirus vaccines

News

Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland

HIV vaccine trial starts at Oxford

News

NDM's Jenner Institute today started vaccinations of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK.

RECOVERY Trial identifies another effective COVID-19 treatment

News

The RECOVERY Trial, the world’s largest randomised trial of potential COVID-19 treatments, has found that a monoclonal antibody combination developed by US company Regeneron reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response.

NDM Researchers recognised in Queen’s Birthday Honours

News

The pioneering work of members of the University, including research into tackling the Coronavirus pandemic, has been recognised in The Queen's Birthday Honours List.

University of Oxford to launch Pandemic Sciences Centre

News

The University of Oxford has today announced the launch of a new centre of global research collaboration and excellence, the Pandemic Sciences Centre. The Pandemic Sciences Centre will harness the strong global research collaborations that the University of Oxford has developed over more than forty years. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats.

RECOVERY trial named David Sackett Trial of the Year 2020

News

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has been named David Sackett Trial of the Year by the Society for Clinical Trials (SCT). The award was presented today at the Society for Clinical Trials’ 42nd Annual Meeting.

Oxford University and Oracle partner to speed identification of COVID-19 variants

News

The partnership will enable global genomic sequencing and examination through a specialist platform developed on Oracle Cloud Infrastructure to help mitigate the impact of potentially dangerous COVID-19 variants.

Five new Academy of Medical Sciences Fellows from NDM

News

The Academy of Medical Sciences has elected 11 University of Oxford biomedical and health scientists to its fellowship five of which are from the Nuffield Department of Medicine. All were selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.

Director of NDM's Jenner Institute elected to The Royal Society

News

Professor Adrian Hill, Director of the Jenner Institute becomes a Fellow for his leading role in the design and development of new vaccines for globally important infectious diseases over the course of over 25 years. He has demonstrated that non-replicating vectored vaccines, particularly simian adenoviruses used in heterologous prime-boost immunisation regimes, can protect safely through cellular as well as humoral immunity – supporting new vaccination approaches for malaria and Ebola.

National survey reveals big reductions in COVID-19 infections with single dose of Oxford-AZ and Pfizer vaccines

News

Data from the national COVID-19 Infection Survey, which is led by senior NIHR Oxford BRC researcher Professor Sarah Walker, has revealed the impact of vaccination on antibody responses and new infections in a large group of adults from the general population. This major community surveillance survey, one of the NIHR’s COVID-19 urgent public health studies, is a partnership between the University of Oxford, the Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC).

CCOUC Webinar on Health-EDRM Education and Research in China: Commemorating the 512 Wenchuan Earthquake

News

You are cordially invited to join the CCOUC Webinar on Health-EDRM Education and Research in China: Commemorating the 512 Wenchuan Earthquake. As a commemoration of the 512 Wenchuan Earthquake in 2008, experts will share with you an update on the latest Health-EDRM Education and Research in China. This is a webinar of the CCOUC 10th Anniversary International Webinar Series on Health Emergency and Disaster Risk Management.

Oxford University researchers release cheap, quick COVID-19 antibody test

News

The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.

The RECOVERY Trial: One year on

News

Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival. From having no known effective drugs when the pandemic first erupted, patients are now offered treatments that have been robustly proven to reduce death and improve other outcomes, such as the length of hospital stay and the need for mechanical ventilation.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

News

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.

Professor Cecilia Lindgren appointed Director of the Big Data Institute

News

Professor Cecilia Lindgren has been appointed as the new Director of the University of Oxford’s Big Data Institute. Professor Lindgren will take up post on 1 April 2021. She succeeds Professor Gil McVean who was the founding director of the BDI, and Interim Director, Professor Martin Landray.

Professor Sarah Gilbert awarded RSA Albert Medal

News

NDM's Professor Sarah Gilbert has been awarded the Royal Society for Arts’ (RSA) Albert Medal for her work on the Oxford vaccine. Professor Gilbert is Professor of Vaccinology and the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.

World’s largest clinical trial for COVID-19 treatments expands internationally

News

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join and recruited to RECOVERY International. NDM's Peter Horby, Professor of Emerging Infectious Diseases and Global Health, and Joint Chief Investigator for the trial, said ‘The RECOVERY trial has been an enormous success, enrolling over 36,000 patients and delivering clear results on six treatments already. By building on this success through international partnership we can speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies".

Load More